American Association for Cancer Research, Clinical Cancer Research, 9(26), p. 2085-2086, 2020
DOI: 10.1158/1078-0432.ccr-20-0387
Full text: Download
Abstract The impact on survival of steroids and TNFα blockade to treat immune-related toxicity from checkpoint blockade with ipilimumab, nivolumab/pembrolizumab, or combined ipilimumab and nivolumab was assessed using data from a large national database. Using steroids was associated with better survival than the use of TNFα-blocking antibodies such as infliximab. See related article by Verheijden et al., p. 2268